Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Solá, C.
Right arrow Articles by Estapé, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Solá, C.
Right arrow Articles by Estapé, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 4:313-316, 1993
© 1993 European Society for Medical Oncology

research-article

Carboplatin, methotrexate, vinblastine and epirubicin (Carbo-MVE) for transitional cell bladder carcinoma

C. Solá, J. Mallafré, L. Mendoza Solórzano, A. Segarra, M. Daniels, N. Vinolas, A. Alcaraz, M. Solé, R. Alvarez, A. Biete and J. Estapé

Bladder Cancer Committee, Clinic Hospital, School of Medicine, Barcelona University Barcelona, Spain

Correspondence to: Claudio Sola, M.D. Medical Oncology Department Sant Pau Hospital 167 San Antonio Maria Claret 08025 Barcelona, Spain

BACKGROUND:: MVAC is considered the most effective chemotherapy regimen for transitional cell bladder carcinoma However, due to its significant toxic effects we substituted carboplatin for cisplatin and epirubicin for adriamycin in an attempt to produce the same response with less toxicity.

PATIENTS AND METHODS:: Twenty-seven patients with invasive transitional cell bladder carcinoma received Carbo-MVE: carboplatin (300 mgr/m2 d2), methotrexate (30 mgr/m2 dl, 15, 22), vinblastine (3 mgr/m2 d2,15, 22) and epirubicin (30 mgr/m2 d2) every 4 weeks.

RESULTS:: There were 2 complete clinical responses (8.4%), 5 partial clinical responses (20.8%), 8 stabilizations (33.3%) and 9 progressions (37.5%). The overall clinical response rate was 29.2% (ll%-47.4%, 95% CI), but 2 partial clinical remissions were not pathologically confirmed; were they to be considered as non-responses the response rate would fall even lower (20.8%). Toxicity was moderately severe, with 77.8% developing WHO grade 111-IV granulocytopenia, 22.2% grade III-IV thrombocytopenia and 59.3% grade II-in vomiting. There were no toxic deaths nor any renal toxicity.

CONCLUSIONS:: Our results suggest that Carbo-MVE is less active and at least as hematotoxic as multiagent CDDP-based regimens.

invasive bladder cancer, chemotherapy, carboplatin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.